Targeted missile drug joins fight against Tough-to-Treat lymphomas
NCT ID NCT04479267
Summary
This study is testing whether adding a new targeted drug called polatuzumab vedotin to standard chemotherapy works better for people with aggressive types of B-cell lymphoma. The trial aims to see if this combination helps more patients achieve complete remission and controls the disease longer. It's for adults newly diagnosed with specific fast-growing lymphomas who haven't had treatment yet.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
Conditions
Explore the condition pages connected to this study.